Peter K.  Miller net worth and biography

Peter Miller Biography and Net Worth

CEO of OptiNose
Mr. Miller has served as our Chief Executive Officer and as a member of our Board of Directors since 2010, and previously as a member of the board of directors of OptiNose AS from 2008 to 2010.

From June 2004 to May 2007, Mr. Miller was Co-Founder, Chief Executive Officer and President of Take Care Health Systems Inc., a company that introduced medical clinics inside Walgreens retail pharmacies, and from May 2007 to May 2010, served as Vice President of Walgreen Co.’s Health and Wellness Division following its acquisition of Take Care Health Systems.

Prior to co-founding Take Care Health Systems, Mr. Miller spent more than 15 years at Johnson & Johnson, a multinational medical devices, pharmaceutical and consumer packaged goods manufacturer, serving in a variety of marketing and general management roles that included Worldwide President of Johnson & Johnson — Merck Consumer Pharmaceuticals and President of Janssen Pharmaceutical. Mr. Miller served as a member of the board of directors of Actua Corporation, a publicly-traded SaaS technology company, from June 2010 until January 2018.

Mr. Miller holds a B.S. in Economics from Trinity College and an M.B.A. from the Kellogg School of Management at Northwestern University.

What is Peter K. Miller's net worth?

The estimated net worth of Peter K. Miller is at least $520,561.80 as of January 13th, 2023. Mr. Miller owns 56,892 shares of OptiNose stock worth more than $520,562 as of March 29th. This net worth estimate does not reflect any other investments that Mr. Miller may own. Learn More about Peter K. Miller's net worth.

How do I contact Peter K. Miller?

The corporate mailing address for Mr. Miller and other OptiNose executives is 1020 STONY HILL ROAD SUITE 300, YARDLEY PA, 19067. OptiNose can also be reached via phone at (267) 364-3500 and via email at investors@optinose.com. Learn More on Peter K. Miller's contact information.

Has Peter K. Miller been buying or selling shares of OptiNose?

Peter K. Miller has not been actively trading shares of OptiNose over the course of the past ninety days. Most recently, Peter K. Miller sold 1,977 shares of the business's stock in a transaction on Friday, January 13th. The shares were sold at an average price of $26.55, for a transaction totalling $52,489.35. Following the completion of the sale, the chief executive officer now directly owns 56,892 shares of the company's stock, valued at $1,510,482.60. Learn More on Peter K. Miller's trading history.

Who are OptiNose's active insiders?

OptiNose's insider roster includes Victor Clavelli (Insider), Keith Goldan (CFO), Ramy Mahmoud (COO), Michael Marino, III (Insider), and Peter Miller (CEO). Learn More on OptiNose's active insiders.

Are insiders buying or selling shares of OptiNose?

In the last year, insiders at the sold shares 9 times. They sold a total of 20,872 shares worth more than $261,223.65. The most recent insider tranaction occured on March, 18th when insider Michael F Marino III sold 246 shares worth more than $1,380.06. Insiders at OptiNose own 2.3% of the company. Learn More about insider trades at OptiNose.

Information on this page was last updated on 3/18/2025.

Peter K. Miller Insider Trading History at OptiNose

See Full Table

Peter K. Miller Buying and Selling Activity at OptiNose

This chart shows Peter K Miller's buying and selling at OptiNose by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$100k$0$100kTotal Insider BuyingTotal Insider Selling

OptiNose Company Overview

OptiNose logo
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.
Read More

Today's Range

Now: $9.15
Low: $9.13
High: $9.17

50 Day Range

MA: $6.30
Low: $5.27
High: $9.17

2 Week Range

Now: $9.15
Low: $4.82
High: $22.35

Volume

93,294 shs

Average Volume

63,045 shs

Market Capitalization

$92.05 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A